Literature DB >> 29028281

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.

Ramy Younes1, Chiara Rosso1, Salvatore Petta2, Monica Cucco1, Milena Marietti1, Gian Paolo Caviglia1, Alessia Ciancio1, Maria Lorena Abate1, Carlo Cammà2, Antonina Smedile1, Antonio Craxì2, Giorgio Maria Saracco1, Elisabetta Bugianesi1.   

Abstract

BACKGROUND & AIMS: The non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis.
METHODS: We analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness (LS) by Fibroscan were assessed within three months from liver biopsy.
RESULTS: The diagnostic accuracy of ION for the identification of NASH was not as satisfactory as reported (area under the ROC curve, AUROC = 0.687 [95% CI = 0.62-0.75]). The proposed cut-off value ≥50 showed a poor sensitivity (Se) (28%) and a good specificity (Sp) (92%), with a positive predictive value (PPV) of 91% and a negative predictive value (NPV) of 30%. A new cut-off value >26 improved Se (73%) but decreased Sp (60%) (PPV of 84% and a NPV of 43%). ION performed slightly better in obese NAFLD (AUROC = 0.700). The combination of ION and markers of fibrosis did not improve the identification of advanced liver disease.
CONCLUSIONS: ION is not feasible for the non-invasive diagnosis of NASH across different populations of NAFLD patients, mainly because its limited reproducibility in non-obese subjects.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  fibrosis; non-invasive marker; steatohepatitis

Mesh:

Substances:

Year:  2017        PMID: 29028281     DOI: 10.1111/liv.13612

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  2 in total

1.  acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.

Authors:  Xi-Xi Wu; Kenneth I Zheng; Jérôme Boursier; Wah-Kheong Chan; Yusuf Yilmaz; Manuel Romero-Gómez; Mohamed El Kassas; Giovanni Targher; Christopher D Byrne; Zhi-Ming Huang; Ming-Hua Zheng
Journal:  EClinicalMedicine       Date:  2021-10-01

2.  Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.

Authors:  Ferenc Emil Mózes; Jenny A Lee; Emmanuel Anandraj Selvaraj; Arjun Narayan Ajmer Jayaswal; Michael Trauner; Jerome Boursier; Céline Fournier; Katharina Staufer; Rudolf E Stauber; Elisabetta Bugianesi; Ramy Younes; Silvia Gaia; Monica Lupșor-Platon; Salvatore Petta; Toshihide Shima; Takeshi Okanoue; Sanjiv Mahadeva; Wah-Kheong Chan; Peter J Eddowes; Gideon M Hirschfield; Philip Noel Newsome; Vincent Wai-Sun Wong; Victor de Ledinghen; Jiangao Fan; Feng Shen; Jeremy F Cobbold; Yoshio Sumida; Akira Okajima; Jörn M Schattenberg; Christian Labenz; Won Kim; Myoung Seok Lee; Johannes Wiegand; Thomas Karlas; Yusuf Yılmaz; Guruprasad Padur Aithal; Naaventhan Palaniyappan; Christophe Cassinotto; Sandeep Aggarwal; Harshit Garg; Geraldine J Ooi; Atsushi Nakajima; Masato Yoneda; Marianne Ziol; Nathalie Barget; Andreas Geier; Theresa Tuthill; M Julia Brosnan; Quentin Mark Anstee; Stefan Neubauer; Stephen A Harrison; Patrick M Bossuyt; Michael Pavlides
Journal:  Gut       Date:  2021-05-17       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.